Organisation

Top Institute Pharma - TI Pharma

Pagina-navigatie:

Main
Current research (38)
Completed research (32)

Completed research

(the most recent research is at the top)
Collaboration	Helminth infections induce immunomodulation; consequences and mechanisms
Collaboration	Functional genomic characterisation of molecular determinants for staphylococcal fitness, virulence and drug resistance (StaphDynamics)
Financier	A Novel Approach to Stimulate Cartilage Repair: Targeting Collagen Turnover
Financier	The CSF proteome / metabolome as primary biomarker compartment for CNS disorders
Financier	Chemical labeling for the analysis of proteins, peptides and metabolites bij mass spectrometry
Financier	Olanzapine-induced weight gain: Lessons learned from developing rat models
Financier	Integrated Analytical Strategies for Drug Discovery
Financier	Modelling of the influence of age-related changes on the pharmacokinetics and pharmacodynamics of drugs; Glucuronidation and analgesic efficacy
Financier	Target validation: Behavioral consequences for cognition of gene knockdown using RNA-interference technology
Financier	Nurturing Nature: Testing the Three-hit Hypothesis of Schizophrenia
Financier	Control of metabolic flux by nutrient sensors
Secretariat	Development of recombinant live and subunit vaccine against Chikungunya virus infections
Secretariat	Neuromodulation of innate immune responses
Secretariat	Immune modulation and tolerance induction, prevention and inhibition of inflammatory diseases
Secretariat	Transition of systemic inflammation into multiorgan pathology
Secretariat	The pathogenesis of lung emphysema: lessons learned from murine models
Secretariat	Knowledge preservation, management and learning
Secretariat	Ethical and societal dilemmas and prospects in the timely and safe availability of new drugs to individuals
Secretariat	Improving patient SAFETY through better methods of clinical risk management
Secretariat	Optimising the benefits and SAFETY of new drugs: prospects pharmacogenetics/-genomics, safety monitoring
Secretariat	The (future) post-marketing phase: requirements and opportunities for better SAFETY research
Secretariat	Use and validation of BIOMARKERS and proxy-outcomes in pre- and post-registration setting
Secretariat	Connecting BIOMARKERS and proxy-outcomes across different phases of drug development
Secretariat	Innovation in the design of research on efficacy and safety of new drugs
Secretariat	Restoring SOCIETAL trust in drug development, regulation and marketing of new drugs
Secretariat	The cost-effectiveness of drug regulation
Secretariat	Improvement of access and reimbursement trajectories and beyond
Secretariat	The quality of post marketing surveillance of biotech drugs
Secretariat	Facilitating drug development by creating the ?ideal? regulatory environment in the context of priority medicines
Secretariat	Scientific and political drivers of the current drug regulatory environment, perspectives for improvement
Secretariat	Getting grip on glucocorticoid-induced metabolic derangements
Secretariat	Nanoscience as a tool for improving bioavailability and blood-brain barrier penetration of CNS drugs